Work

POSTER: CLL-542 High Rates of Undetectable Minimal Residual Disease Remissions With Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL) — an Updated Analysis

Year: 2023

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(23)00527-x

Authors: Andrew Lipsky, Brian Hill, Allison Winter, Joseph Jurcic, Todd Rosenblat, Nicole Lamanna

Institutions: Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4386281981

FWCI:

Cites:

Cited by:

Related to: 10